Hypertrophic Cardiomyopathy
Cardiovascular
5
Pipeline Programs
9
Companies
8
Clinical Trials
2 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
0
2
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 7 programs with unclassified modality
On Market (1)
Approved therapies currently available
U
ASPRUZYO SPRINKLEApproved
ranolazine
Unknown CompanyAnti-anginal [EPC]oral2022
Competitive Landscape
7 companies ranked by most advanced pipeline stage
GS
AstraZenecaCAMBRIDGE, United Kingdom
1 program1
candesartanPhase 2Small Molecule1 trial
Active Trials
NCT00430833Unknown
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Gilead SciencesRanolazine
Edgewise TherapeuticsEDG-7500
Tenaya TherapeuticsTN-201
Viz.aiViz HCM
Bristol Myers SquibbQuality of life assessment
Viz.aiViz HCM ECG Review
AbbottInsertable cardiac monitor
Clinical Trials (8)
Total enrollment: 1,010 patients across 8 trials
Ranolazine for the Treatment of Chest Pain in HCM Patients
Start: Nov 2012Est. completion: May 201614 patients
Phase 4Completed
CHANCE - Candesartan in Hypertrophic Cardiomyopathy
Phase 2Unknown
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
Start: Apr 2024Est. completion: Dec 2026100 patients
Phase 2Active Not Recruiting
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
Start: Aug 2023Est. completion: Aug 2032
Phase 1/2Recruiting
VIZ ACCESS HCM - Multi-Site Registry
Start: Jun 2025Est. completion: Dec 2028500 patients
N/ARecruiting
A Study to Assess Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in Japan
Start: Dec 2023Est. completion: May 2025149 patients
N/ACompleted
Viz HCM (ECG Assist) Utilization Workflow Pilot
Start: Jan 2022Est. completion: Jun 2024217 patients
N/ACompleted
Insertable Cardiac Monitors in Hypertrophic Cardiomyopathy
Start: Aug 2017Est. completion: Apr 201930 patients
N/AUnknown
Related Jobs in Cardiovascular
Embedded Software and System Test Engineer (H/F)
Cardiawave
Levallois-Perret, France (Hybrid)
Just now
Territory Sales Manager - Iowa / Nebraska
HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
Yesterday
From $150K/yr
Associate Regulatory Affairs Specialist
Medtronic
Mounds View, Minnesota, United States of America
Yesterday
$60K - $90K/yr
Business Development Manager, Post Transplant, Cardio Thoracic
Thermo Fisher Scientific
Remote
Yesterday
Director, Medical Affairs
Abbott
Germany - Hesse - Eschborn
Yesterday
Therapy Development Manager
Abbott
Australia > Doncaster : 666 Doncaster Road
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 1,010 patients
9 companies competing in this space